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Abstract Stimulatory G protein-mediated cAMP signal-
ing is intimately involved in skeletal homeostasis. How-
ever, limited information is available on the role of the
cAMP signaling in regulating the differentiation of mes-
enchymal stem cells into mature osteoblasts and adipo-
cytes. To investigate this, we treated primary mouse bone
marrow stromal cells (BMSCs) with forskolin to stimulate
cAMP signaling and determined the effect on osteoblast
and adipocyte differentiation. Exposure of differentiating
osteoblasts to forskolin markedly inhibited progression to
the late stages of osteoblast differentiation, and this effect
was replicated by continuous exposure to PTH. Strikingly,
forskolin activation of cAMP signaling in BMSCs condi-
tioned mesenchymal stem cells (MSCs) to undergo
increased osteogenic differentiation and decreased adipo-
genic differentiation. PTH treatment of BMSCs also
enhanced subsequent osteogenesis, but promoted an
increased adipogenesis as well. Thus, activation of cAMP
signaling alters the lineage commitment of MSCs, favoring
osteogenesis at the expense of adipogenesis.
Keywords Cyclic AMP (cAMP)  Osteogenesis 
Adipogenesis  Parathyroid hormone (PTH)
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Introduction
Fibrous dysplasia (FD, OMIM 174800) of bone is one of
the manifestations of the McCune–Albright syndrome.
Patients with McCune–Albright syndrome have activating
missense mutations in GNAS, the gene encoding the a
subunit of Gs [1–3]. These mutations have been demon-
strated in various tissues, including bones [3–5] and sam-
ples from the monostotic form of fibrous dysplasia [6, 7].
In fibrous dysplasia, the expression of Gs protein and its
transcript is upregulated during the maturation of precursor
osteogenic cells to mature osteoblasts [8]. Examination of
the fibrotic area revealed an excess of cells with features of
pre-osteoblasts, and the abnormal cellular features of
fibrous dysplasia could be reproduced in vitro by the
addition of excess exogenous cAMP to human osteogenic
cells or by stable expression of constitutively active form
of Gsa in human BMSCs [8, 9].
The role of the Gs/cAMP pathway in bone formation is
further highlighted by several findings. Conditional dele-
tion of the a subunit of Gs in osteoblast lineage cells
resulted in reduced trabecular bone formation [10]. Tar-
geted expression in osteoblasts of constitutively active Gs-
coupled G protein-coupled receptors (GPCRs) resulted in
markedly increased trabecular bone mass [11, 12],
whereas expression of a constitutively-active Gi-coupled
receptor produced trabecular osteopenia [13]. Further-
more, expression of an engineered constitutively active
Gs-coupled receptor under the control of the osteoblast-
specific Col1a1 2.3-kb promoter fragment in mice pro-
duced cellular features similar to that of the polyostotic
fibrous dysplasia of McCune–Albright’s syndrome [11].
Alteration of Gs and Gi signallings in osteoblast lineage
cells was able to generate striking, but opposite effects on
skeletal tissues.
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Several extracellular regulators of skeletal function are
known to exert their actions through GPCRs, which are
located in the osteoblast membrane. The best-studied
GPCR that regulates skeletal function is parathyroid hor-
mone 1 receptor or PTH1R [14]. This receptor is coupled to
multiple G proteins, including Gs, Gq, and possibly Gi,
resulting in the activation of diverse downstream effectors
[15–18]. Although PTH activates multiple signaling path-
ways, several lines of evidence indicate that PTH peptide
fragments that specifically stimulate Gs signaling coupled
to PTH1R could increase bone formation [19–22]. PTH
(1–34) was also able to regulate osteogenic development
via cAMP signaling in a BMP-dependent mesenchymal
differentiation system [23]. PTH-induced signaling via
Gs/cAMP pathway plays a particularly important role in
skeletal function.
Mesenchymal stem cells are a pluripotent cell type that
can differentiate into a variety of cell types, including
adipocytes and osteoblasts. Lineage specification is
achieved by the expression of transcription factors Cbfa1/
Runx2 and Osterix in the case of osteogenesis, and PPARc
in the case of adipogenesis. The number of osteoblasts is
partially determined by the lineage specification process.
Mice haploinsufficient for PPARc or Alox15, the lipoxy-
genase that generates oxidized lipid ligands of PPARc,
have high bone mass phenotype [24, 25]. The control of
MSC differentiation into adipocytes and osteoblasts is
important in maintaining a normal physiologic bone mass,
but the signaling pathways and molecular mechanisms that
regulate this process are not well understood.
Cyclic AMP/protein kinase A (PKA) signaling plays a
prominent, but ambiguous, role in mesenchymal cell fate
decision. Treating human MSCs with PTH inhibited adi-
pocyte development induced by a specific cocktail of adi-
pogenic inducers through the cAMP pathway [26].
Activation of cAMP pathway in calcifying vascular cells
derived from primary aortic medial cell cultures resulted in
mineralization, enhanced alkaline phosphatase activity, and
osteoblast-like differentiation [27]. Pretreatment of human
MSCs with a cAMP analog or forskolin, followed by
transplantation, enhanced in vivo bone formation [28, 29].
Specific type 4 phosphodiesterase inhibitors could stimu-
late fibroblast-colony formation, alkaline phosphatase
activity, and calcium deposition by rat bone marrow cells
[30]. In contrast, a high-throughput siRNA library screen
identified components of cAMP pathway as osteogenic
suppressors in human MSCs [31]. Activation of PKA by
IBMX and forskolin in transformed human MSCs
enhanced adipogenesis, while downregulated gene
expression of osteogenic gene markers by suppressing
leptin [32]. In another one of their reports, de Boer and
coworkers [33] observed that cAMP signaling in MSCs
was inhibitory on osteogenesis in rodent models, arguing
that the difference seen in cAMP-stimulated osteogenic
responses could be species-specific.
The role of cAMP pathway in mesenchymal cell fate
decision and the subsequent cellular differentiation may
depend on the developmental stage in which the cAMP
signal is presented. It is important to consider the precise
developmental stage of the cells in which the cAMP signal is
activated. Activating cAMP signal in differentiating osteo-
blasts may promote a different osteogenic response from
activating cAMP signal in MSCs. Likewise activating cAMP
signal in differentiating adipocytes may also promote a dif-
ferent adipogenic response from activating cAMP signal in
MSCs. Therefore, we sought to investigate the role of the
cAMP signaling in regulating the differentiation of MSCs
into mature osteoblasts and mature adipocytes.
Materials and methods
Bone marrow stromal cell (BMSCs) cultures
Primary bone marrow stromal cells were isolated from the
femurs and tibiae of 8- to 10-week-old FVB/N male mice
(The Jackson Laboratory). The cells were collected in pri-
mary culture medium (PCM) consisting of a-modification of
Eagle’s medium, 10 % fetal bovine serum, 100 U/ml peni-
cillin, 100 lg/ml streptomycin, and 0.25 lg/ml Fungizone
(Gibco Cell Culture), and plated onto 10-cm cell culture
dishes at a density of 7 9 106 cells/dish. Cells were incu-
bated at 37 C with 5 % CO2 and maintained undisturbed for
five days to allow for cell attachment.
PTH, forskolin, and Wnt3a administrations
Human PTH [1–34] (Bachem product # H-4835), forskolin
(Sigma product # F6886), and recombinant mouse Wnt3a
(R&D Systems product # 1324-WN) were dissolved in
acetic acid (4.07 lM final concentration), ethanol (0.82 %
final concentration), and PBS containing 0.1 % bovine
serum albumin, respectively.
Day 5 to day 23 PTH treatment
After incubating BMSCs in PCM for five days, PCM was
removed along with all non-adherent cells. The remaining
adherent cells containing MSCs were exposed to 10-7 M
hPTH in osteoblast differentiation medium (see ‘‘Initiation
of osteoblast differentiation’’ section) from day 5 to day 23.
Day 5 to day 10 forskolin treatments
After removal of non-adherent cells, adherent MSCs were
exposed to forskolin at final concentrations of 0.001, 0.01,
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0.05, and 0.1 mM from day 5 to day 10 in osteoblast dif-
ferentiation medium.
Day 0 to day 5 PTH, forskolin, and Wnt3a treatments
Freshly isolated BMSCs were exposed to hPTH and for-
skolin at the above-mentioned concentrations from day 0 to
day 5 in PCM (Fig. 1a, b). Freshly isolated BMSCs were
exposed to Wnt3a at a final concentration of 25 ng/ml from
day 0 to day 5 in PCM (Fig. 1a).
Day 0 to day 10 forskolin treatments
Freshly isolated BMSCs were exposed to forskolin at final
concentrations of 0.001, 0.01, 0.05, and 0.1 mM from day
0 to day 5 in PCM. PCM containing forskolin was removed
at day 5 along with non-adherent cells. Adherent cells were
exposed to forskolin at these concentrations from day 5 to
day 10 in osteoblast differentiation medium.
Initiation of osteoblast differentiation
After primary BMSCs had been maintained in primary
medium for five days, the medium was aspirated and
replaced with secondary osteogenic differentiation medium
(primary medium containing 50 lg/ml ascorbic acid and
3 mM b-glycerolphosphate) to initiate osteoblast differen-
tiation. Thereafter, secondary differentiation medium was
replaced every two or three days (Fig. 1a).
Initiation of adipogenesis
BMSCs were plated in 6-well plates at 1 9 107 cells/well
and remained in PCM for 10 days. At day 10, the medium
was replaced with secondary adipogenic differentiation
medium (addition of 1 lM rosiglitazone, 1 lM dexa-
methasone, 5 lg/ml insulin, and 500 lM IBMX), and cells
were maintained in it for 2 days. After 2 days, this medium
was replaced with PCM containing 5 lg/ml insulin, and
cells were incubated in it for another 2 days. Cells were
then maintained in PCM until day 19 (Fig. 1b).
Von Kossa and alkaline phosphatase (ALP) staining
of osteoblasts and mineralized nodules
The presence of alkaline phosphatase activity was identi-
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Fig. 1 In vitro mesenchymal stem cell differentiation protocols to
evaluate the effects of PTH and forskolin stimulation of cAMP signal
in MSCs on subsequent osteogenesis or adipogenesis. a Mouse
BMSCs were freshly isolated from long bones and plated in primary
culture medium in the presence of PTH or forskolin and their
respective vehicle controls. At day 5, PTH or forskolin was removed
and cells were induced to differentiate into osteoblasts. Osteoblasto-
genesis was allowed to continue until it was terminated on day 23.
b BMSCs were freshly isolated and plated in primary medium in the
presence of PTH or forskolin and their respective vehicle controls. At
day 5, PTH or forskolin was removed, and fresh medium was added to
the cells. At day 10, adipogenesis was initiated by the addition of
rosiglitazone, dexamethasone, insulin, and IBMX. Differentiation
medium was replaced on day 12 with medium containing insulin only.
Insulin was removed on day 14 and cells were cultured in primary
medium until day 19
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product # 85L2-1KT). Two percent silver nitrate (Sigma
product # S8157) solution was added to cell culture dishes
for Von Kossa staining and UV-crosslinked for 10 min.
Staining solution was then aspirated, and stained dishes
were rinsed twice with distilled water. Stained cultures
were scanned and quantified by means of Improvision
Openlab software version 5.0.2.
Oil Red O staining for lipid accumulation
in differentiated cells
Cells in 6-well plates were fixed in PBS containing 10 %
formaldehyde. Following fixation, cells were stained in Oil
Red O for 15 min. Cells were rinsed several times with
distilled water to remove excess stain. Stained cultures
were scanned and quantified by means of Improvision
Openlab software version 5.0.2.
RNA extraction and quantitative real-time PCR
(qRT-PCR)
Total RNA from BMSCs and osteoblast cultures were
isolated using PureLink Micro-to-Midi total RNA purifi-
cation system (Ambion Cat. # 12183-018) and further
purified using RNeasy Mini Kit (Qiagen Cat. # 74104).
Reverse transcription was carried out using TaqMan
Reverse Transcription Reagents (Applied Biosystems Part
# N808-0234). Gene expression was quantified by SYBR
Green I-based quantitative real-time PCR utilizing SYBR
Green PCR Master Mix (Applied Biosystems part #
4309155). Primers were synthesized by Elim Biopharma-
ceuticals, Inc. (Table 1). PCR was carried out in Applied
Biosystems 7900HT real-time thermocycler. The results
were analyzed by means of 7300 System SDS version 1.4
supplied with the machine.
Statistical analysis
Data are presented as mean ± standard error of at least
three independent experiments. Statistical differences
between the means were examined by Student’s t test by
means of GraphPad Prism 5 software, and significance was
set at a P value of \0.05.
Results
Effects of PTH and forskolin activation of cAMP
signaling in differentiating osteoblasts on osteogenesis
To test the effects of long-term exposure to PTH on dif-
ferentiating osteoblasts, we exposed osteoblasts continu-
ously to PTH from the time when osteoblast differentiation
(day 5) was induced until it was terminated (day 23).
Continuous long-term exposure to PTH completely abol-
ished the appearance of Von Kossa-stained mineralized
nodules in the cell culture (Fig. 2a). However, total ALP
activities in culture was not affected by exposure to PTH
(Fig. 2a, c), suggesting that continuous PTH treatment on
differentiating osteoblasts primarily affected osteoblasts’
ability to mineralize.
To determine whether the effects of PTH on differen-
tiating osteoblasts were exerted through the cAMP/PKA
pathway, we pharmacologically stimulated cAMP signal-
ing using an activator of adenylate cyclase, forskolin.
Exposing osteoblasts to different concentrations of for-
skolin immediately after initiation of osteoblast differen-
tiation for five days (from day 5 to day 10) significantly
reduced the total mineralized area and total mineralized
colony number (Fig. 3a). This decrease in total mineral-
ized area and total mineralized colony number was dos-
age dependent (Fig. 3b, c). However, total ALP activity in
culture was not affected (Fig. 3d), similar to what was
observed in osteoblast cultures that were treated with PTH
continuously from day 5 to day 23. We also examined the
effects of long-term intermittent exposure to forskolin
(cells in the presence of forskolin every other two days or
2 h per day) from day 5 to day 23. Although Von Kossa
staining was completely abolished, ALP activity could not
be accurately measured as the cells appeared to be dying
from the toxic effects of long-term exposure to forskolin
(data not shown). Therefore, we concluded that a transient
Table 1 Sequence of primers
used in qRT-PCR
Gene Forward primer Reverse primer
Runx2 CGAGACCAACCGAGTCATTT ACGCCATAGTCCCTCCTTTT
Osterix TTTCTCATTAACTCGTTGCCATCT CTTCGGGAAAACGGCAAATA
Collagen 1a1 GCGAAGGCAACAGTCGCT CTTGGTGGTTTTGTATTCGATGAC
Osteocalcin CTGACCTCACAGATGCCAAG GTAGCGCCGGAGTCTGTTC
Alkaline phosphatase GCACCTGCCTTACCAACTCT TGGAGTTTCAGGGCATTTTT
Axin 2 TGACTCTCCTTCCAGATCCCA TGCCCACACTAGGCTGACA
Lef 1 AGAAATGAGAGCGAATGTCGTAG CTTTGCACGTTGGGAAGGA
Tcf 1 GTTCACCCACCCATCCTTGAT TGCCTGTGTTTTCAGGTTTCT
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elevation in cAMP signaling in differentiating osteoblasts
negatively regulated mineralization, but had no effect on
the number of ALP-positive cells.
Effects of PTH and forskolin activation of cAMP
signaling in BMSCs on subsequent osteogenesis
To examine the effects of exposing MSCs to PTH on the
subsequent osteoblast differentiation, freshly isolated
BMSCs were exposed to PTH for five days. Before the
induction of osteoblast differentiation, cells from bone
marrows that had attached to culture dishes were allowed
to differentiate later in the absence of PTH (Fig. 1a). We
presumed that most of the attached cells were of mesen-
chymal origin and likely MSCs. BMSCs that were exposed
to PTH were able to produce a 34 % increase in
mineralization and a 27 % increase in the total level of
ALP activity over vehicle-treated control cultures (Fig. 2b,
c). Thus, treating BMSCs with PTH enhanced the ability of
osteoblasts to mineralize and increased the number of
ALP-positive cells.
We then investigated the effects of forskolin treatment
of BMSCs on subsequent osteoblast differentiation. Freshly
isolated BMSCs were immediately exposed to different
doses of forskolin for five days before the initiation of
osteogenesis (Fig. 1a). Exposure to forskolin during this
five-day period promoted an increased osteogenesis as
measured by Von Kossa staining of mineralized nodules
(Fig. 4a). This increase in the mineralization was dose
dependent (Fig. 4b, c). Forskolin treatment resulted in a
78 % increase in total ALP activity over vehicle-treated
control by day 18 (Fig. 4d). Similar to PTH, exposing
control             PTH (day 5 to day 23) 




Fig. 2 Long-term exposure to PTH during osteogenesis completely
abolished mineralization, but exposure to PTH for five days before
initiation of osteogenesis stimulated osteogenesis. a Von Kossa
staining showed no mineralized nodules in cultures that were
continuously exposed to 10-7 M hPTH [1–34] from day 5 to day
23. (Von Kossa-positive mineralized nodules are stained black.
Alkaline phosphatase (ALP)-positive areas are stained purple.)
b Exposure to PTH from day 0 to day 5 modestly increased both
total Von Kossa-stained area and total ALP-positive area. c Total
colony area positive for Von Kossa staining and total ALP-positive
colony area were quantified as percent of basal level of control. Data
are mean ± SEM. *P \ 0.05 and ***P \ 0.001 vs. control; n = 3.
Unfilled bars represent osteoblast cultures that were exposed to PTH
from day 5 to day 23. Filled bars represent BMSC cultures that were
exposed to PTH from day 0 to day 5 prior to induction of osteogenesis
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BMSCs to forskolin increased mineralization as well as
ALP-positive cell numbers.
Activation of cAMP signaling in MSCs by forskolin for
five days promoted a greatly enhanced osteogenesis. Con-
currently, there was an increase in the expression of genes
associated with osteoblast differentiation. Quantitative
real-time PCR demonstrated a significant increase in the
level of transcripts encoding Runx2 and osteocalcin at day
14 and day 18 over the vehicle-treated controls as a result
of forskolin treatment (Fig. 5a). Transcripts encoding Os-
terix and ALP were also significantly increased at day 18,
as compared to the controls (Fig. 5a). Collagen 1a1 gene
expression was significantly elevated at day 14 but not at
day 18 (Fig. 5a).
Combined effects of forskolin activation of cAMP
signaling in BMSCs and differentiating osteoblasts
on osteogenesis
To determine whether the anabolic effect of activated
cAMP signaling in BMSCs on subsequent osteogenesis
could be maintained in differentiating osteoblasts receiving
continuously activated cAMP signaling, BMSCs were
treated with forskolin from day 0 to day 5, and remaining
adherent cells were continuously exposed to freshly added
forskolin from day 5 to day 10, after induction of osteo-
genesis. Continued exposure to forskolin at 0.1 mM for
five days after initiation of osteogenesis completely sup-
pressed the increase in total Von Kossa-positive colony
control Forskolin




Fig. 3 Five-day treatment with forskolin after initiation of osteoblast
differentiation diminished osteoblast mineralization. a Exposure to
0.1 mM forskolin immediately after initiation of osteogenesis for
5 days reduced Von Kossa staining of mineralized nodules, b total
Von Kossa-positive colony area, and c total Von Kossa-positive
colony number. d No changes in ALP-positive total colony area were
detected. Data were quantified as percent of basal level of control and
represent mean ± SEM. *P \ 0.05 vs. vehicle-treated controls;
n = 3
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area (Fig. 6a) stimulated by five-day 0.1 mM forskolin
exposure before osteogenic induction. Continued exposure
to forskolin at this dose also significantly reduced Von
Kossa-positive colony number relative to the vehicle con-
trol (Fig. 6b). When cells were exposed to forskolin at
lower doses from day 0 to day 10, the anabolic effect of
forskolin was maintained as assessed by both Von Kossa-
positive colony area and number (Fig. 6a, b). Interestingly,
the total ALP-positive colony area resulting from the
forskolin treatment at all concentrations was not altered
relative to the vehicle control (Fig. 6c). The increase in
ALP-positive colony area resulted from 5-day 0.1 mM
forskolin activation in BMSCs was suppressed, but not
below the level of the vehicle-treated control.
Effects of PTH and forskolin activation of cAMP
signaling in BMSCs on subsequent adipogenesis
Our results suggest that induction of cAMP signaling in
pluripotent MSCs favors differentiation to osteogenic cells.
If so, then differentiation of other lineages such as adipo-
genesis might be inversely affected. To test this, we pro-
ceeded with the same forskolin treatment, but induced MSCs
to become adipocytes. Following our standard protocol,
0.001mM      0.01mM 0.05mM 0.1mM




Fig. 4 Treatment of MSCs with forskolin followed by induction of
osteoblast differentiation resulted in a dose-dependent increase in
osteogenesis. Primary mouse BMSCs were exposed to different
concentrations of forskolin for five days before induction of osteoblast
differentiation. a Exposure to forskolin during the 5-day period was
able to promote more efficient osteogenesis as indicated by increased
Von Kossa staining of mineralized nodules at day 23. b Total colony
area stained positive for Von Kossa staining and c total Von Kossa-
positive colony number were quantified as percent of basal level of
control. d Osteoblast differentiation was terminated at day 10, day 14,
day 18, and day 22 to detect for ALP activity at different time points
of osteoblast differentiation. Treatment of BMSCs with forskolin
followed by induction of osteoblast differentiation resulted in an
increase in ALP-positive colony area by day 18. ALP activity was
quantified as percent of basal level of control. Data are mean ± SEM.
**P \ 0.01 and ***P \ 0.001 vs. vehicle-treated controls; n = 3
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adipogenesis was initiated at day 10, instead of day 5 in the
osteogenesis protocol. In contrast to an enhanced osteogenic
response, activation of cAMP signaling in MSCs diminished
the efficiency of adipogenesis in a dose-dependent manner,
as assessed by Oil Red O staining (Fig. 7a, b). There was a
dose-dependent decrease in Oil Red O-positive colony
Fig. 5 a Treatment of MSCs with forskolin followed by induction of
osteogenesis resulted in upregulated expression of osteoblast marker
gene in late stages of osteoblast differentiation. MSCs were exposed
to 0.1 mM of forskolin from day 0 to day 5 before induction of
osteoblast differentiation. RNA was isolated from day 10, 14, and 18
of osteoblast cultures. Quantitative real-time RT-PCR was carried out
to detect changes in marker gene expression as a result of forskolin
treatment. Transcript levels were quantified relative to the average of
the expression levels of the internal housekeeping genes, L19 and
Hprt1. Data are mean ± SEM. *P \ 0.05; n = 3. Unfilled bars
represent control MSC cultures that were not exposed to forskolin
while filled bars represent cultures that were exposed to forskolin
from day 0 to day 5 prior to induction of osteogenesis. b ALP gene
expression was upregulated, while PPARc gene expression was
downregulated in MSCs following five days of exposure to forskolin.
Reverse transcription and real-time qPCR were performed on RNA
isolated from MSCs treated with 0.1 mM forskolin or 10-7 M hPTH
[1–34] and their respective vehicle controls from day 0 to day 5. ALP
transcript levels were quantified relative to the average of the
expression levels of the internal housekeeping genes, L19 and Hprt1.
PPARc transcript levels were quantified relative to the expression of
L19. Data are mean ± SEM. #P \ 0.05; n C 3
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number (Fig. 7c), suggesting that activation of cAMP sig-
naling in MSCs promoted more MSCs to commit toward the
osteogenic pathway and concomitantly reduced the number
of MSCs committed toward the adipogenic pathway.
Next, we examined the effect of exposing BMSCs to
PTH on subsequent adipogenesis. PTH treatment on
BMSCs for five days actually produced a modest increase
(27 %) in the subsequent adipogenesis as measured by Oil
Red O staining (Fig. 7d, e). However, the total Oil Red
O-positive colony number was not significantly affected
(Fig. 7f). Unlike the effects of forskolin, PTH treatment on
BMSCs did not reduce the subsequent adipogenesis.
Expression of early gene markers of osteogenesis
and adipogenesis in MSCs following five-day forskolin
treatment
Although forskolin treatment of BMSCs increased expres-
sion of genes associated with osteoblast differentiation,
changes in the expression of these genes might only reflect
the altered efficiency of osteoblast differentiation. Critical
changes at the molecular level might have already occurred
at earlier stages of differentiation process. Therefore, we
examined changes in the expression of early marker genes
before the induction of differentiation. Transcript levels of
three early markers of osteogenesis (Runx2, Osterix, and
ALP) and three early markers of adipogenesis (C/EBP,
PPARc, and ADRP) were measured after five-day forskolin
or PTH treatment. Exposure to forskolin increased the ALP
transcript level in MSCs by 17 fold over vehicle-treated
controls (Fig. 5b). On the other hand, PPARc was down-
regulated by more than forty percent (Fig. 5b). No signifi-
cant changes in transcript levels were detected in other genes
(data not shown). Five-day exposure to PTH had little impact
on the expression of any of these early marker genes in MSCs
(data not shown). Thus, forskolin was able to alter the gene
expression of ALP and PPARc prior to the start of differ-
entiation process.
Canonical Wnt pathway as a mediator of PTH/cAMP
action in MSCs
Wnt/b-catenin pathway plays an important role in normal
bone biology, and deregulation of this process contributes
Fig. 6 Five-day forskolin-





signaling in BMSCs. Primary
mouse BMSCs were exposed to
different concentrations of




after induction for further five
days. a Continued 0.1 mM
forskolin treatment after
induction of differentiation
reduced total Von Kossa-
positive colony area, b Von
Kossa-positive colony number
but not c total ALP-positive
colony area. Data were
quantified as percent of basal
level of control and represent
mean ± SEM. *P \ 0.05,
**P \ 0.01, and ***P \ 0.001
vs. vehicle-treated controls;
n = 3
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to bone diseases [34–36]. Emerging data suggest that
canonical Wnt signaling promotes maturation of osteo-
blastic precursor cells into mature osteoblasts [37, 38]. To
determine whether cAMP signaling exerts its action
through Wnt/b-catenin pathway in MSCs, we measured
transcript levels of canonical Wnt target genes in MSCs
that had been treated with forskolin from the time of
plating until day 5. Gene expression of Tcf1 and Lef1 was
not significantly altered by forskolin treatment; however,
expression of Axin2 was upregulated by five-fold (Fig. 8a).
Activating Wnt/b-catenin pathway by exposing MSCs to
Wnt3a for the same duration significantly increased
expression of Axin2, Tcf1, and Lef1 (Fig. 8a). Expression
of these Wnt target genes were also examined in MSCs
exposed to PTH. No changes in the transcript levels of
these genes were detected (data not shown). Despite an
increased expression of Axin2, forskolin activation of
cAMP signaling in MSCs did not increase the expression of
A
B C
0.001mM              0.01mM               0.05mM                0.1mM
Forskolin Forskolin                Forskolin                Forskolin
Forskolin control  Forskolin PTH control PTH 
D
E F
Fig. 7 Treatment of MSCs with forskolin followed by induction of
adipogenesis resulted in a dose-dependent decrease in adipogenesis,
while treatment of MSCs with PTH followed by induction of
adipogenesis resulted in a modest increase in adipogenesis. Mouse
BMSCs were exposed to different concentrations of forskolin from
day 0 to day 5 before induction of adipogenesis at day 10. a Oil Red O
staining of lipid contents of the cell indicated the degree of
adipogenesis. b Total colony area stained positive for Oil Red O
staining and c total Oil Red O-positive colony number were quantified
as percent of basal level of control. Data are mean ± SEM.
*P \ 0.05, **P \ 0.01, and ***P \ 0.001; n = 3. Mouse BMSCs
were exposed to 0.1 mM of forskolin or 10-7 M of hPTH [1–34]
from day 0 to day 5 before induction of adipogenesis at day 10. d Oil
Red O stained for lipid content of the cell. e Total colony area stained
positive for Oil Red O staining and f total colony number stained
positive for Oil Red O were quantified as percent of basal level of
control. Data are mean ± SEM. *P \ 0.05, ***P \ 0.001; n = 4
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other classical canonical Wnt target genes, which were
upregulated by Wnt3a. When mineralization of osteoblasts
was examined following 5-day Wnt3a treatment on
BMSCs, Wnt3a actually conditioned the cells to less effi-
ciently differentiate into mature osteoblasts, as indicated by
reduced total Von Kossa-positive colony area, Von Kossa-
positive colony number, and ALP-positive area (Fig. 8b).
The effects of exposing BMSCs to forskolin or PTH on
subsequent osteogenesis were not mediated by the canon-
ical Wnt signaling pathway.
Discussion
Precisely, how Gs-mediated cAMP signaling regulates
MSC development remains controversial. In this paper, we
explored the direct involvement of cAMP pathway in
regulating MSC differentiation and demonstrated that
stimulating cAMP signaling in MSCs enhanced osteogenic
response, while continuous activation of cAMP signaling
in differentiating osteoblasts negatively affected minerali-
zation. Furthermore, stimulating cAMP signaling in
MSCs favored osteogenic development over adipogenic
development.
First, we used natural ligand, PTH, to activate the cAMP
pathway in developing osteoblasts and MSCs. Using pri-
mary mouse BMSCs as the source of MSCs, we tested the
effects of long-term exposure to PTH after initiation of
osteogenesis. Long-term exposure to PTH during differ-
entiation completely abolished the osteoblasts’ ability to
mineralize, but not the number of ALP-positive colonies.
On the other hand, treatment of BMSCs with PTH,
Fig. 8 a Effects of five-day
exposure to forskolin or Wnt3a
on Wnt target gene expression
in mesenchymal stem cells.
MSCs were treated with
0.1 mM of forskolin or 25 ng/
ml of Wnt3a and their
respective vehicle controls from
day 0 to day 5. RNA was
isolated on day 5 and subjected
to quantitative real-time RT-
PCR. Gene expression was
quantified relative to the
expression of L19. b Treatment
of MSCs with Wnt3a followed
by induction of osteoblast
differentiation resulted in
decreased osteogenesis. Primary
mouse BMSCs were exposed to
25 ng/ml of Wnt3a for 5 days
before induction of osteoblast
differentiation. Exposure to
Wnt3a during the 5-day period
produced less efficient
osteogenesis as indicated by
reduced total Von Kossa-
positive colony area, Von
Kossa-positive colony number,
and ALP-positive colony area.
Von Kossa and ALP staining
were quantified as percent of
basal level of control. Data are
mean ± SEM. *P \ 0.05,
**P \ 0.01, and ***P \ 0.001
vs. vehicle-treated controls;
n = 3
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followed by induction of osteogenesis, resulted in a modest
increase in osteogenesis. As such, PTH produced varied
effects on the mineralization potential of osteoblasts
depending on the developmental stage of the cells.
PTH can also activate the MAPK cascade through Gi, as
well as the phospholipase C pathway via Gq signaling.
Therefore, forskolin was used to directly stimulate the
production of cAMP to examine the specific role of cAMP
signaling pathway in MSC differentiation. Stimulation of
cAMP signaling by forskolin in differentiating osteoblasts
for five days resulted in diminished osteogenesis, both in
terms of total area of mineralization and number of min-
eralizing colonies. Thus, exposing differentiating osteo-
blasts to PTH or forskolin greatly reduced osteoblasts’
ability to mineralize.
Direct activation of cAMP signaling by forskolin in
BMSCs yielded an osteogenic response that was opposite
of activating cAMP signaling in differentiating osteoblasts.
In addition to increased mineralization, there was an
increase in the number of ALP-positive colonies. Dosage-
dependent increase in the ratio of Von Kossa signal over
ALP signal (data not shown) indicated that cAMP signaling
in BMSCs conditioned the cells to more efficiently dif-
ferentiate into osteoblasts, particularly their ability to
mineralize. Elevated expression of osteoblast marker genes
such as Runx2, Osterix, Collagen 1a1, Osteocalcin, and
ALP at the late stages of differentiation also implied a
more efficient osteoblast differentiation. As to why modest
increase in gene expression of Collagen 1a1 and Osteo-
calcin could result in strong mineralization, one possibility
is that early expression of ALP (before osteogenic induc-
tion) could act to increase local concentration of inorganic
phosphate, a mineralization promoter, and to decrease the
concentration of extracellular pyrophosphate, an inhibitor
of mineral formation [39]. Conversely, the effect of direct
activation of cAMP signaling in BMSCs on adipogenesis
was negative. Activation of cAMP signaling in mesen-
chymal cells, which were earlier in their development,
might impart in them an ability to more efficiently differ-
entiate into mature osteoblasts and less efficiently differ-
entiate into mature adipocytes.
Activation of cAMP signaling by forskolin in BMSCs
produced increased number of ALP-positive osteogenic
colonies and decreased number of adipogenic colonies as
measured by total Oil Red O staining. Expressions of early
osteogenic and adipogenic marker genes were examined in
MSCs which had been exposed to forskolin to determine
changes in osteogenic or adipogenic potential of MSCs.
ALP gene expression was greatly upregulated in MSCs that
had been exposed to forskolin although the same treatment
with PTH did not alter its expression. Conversely, PPARc
gene expression was downregulated in MSCs by forskolin
treatment. Interestingly, the elevated ALP transcript level
was not maintained once cells had been induced to dif-
ferentiate into osteoblasts (Fig. 5, day 10) and recovered
only in later stages of osteogenesis (Fig. 5, day 18). We do
not know the biologic relevance of this transcriptional
response. Perhaps, ALP transcriptional activation requires
continuous presence of forskolin, thus it could be a direct
target of cAMP signaling. Sustained elevated cAMP sig-
naling in MSCs might have produced epigenetic changes
that altered the transcriptional control of specific promot-
ers. Recently, a PKA-dependent histone lysine demethylase
complex had been characterized, suggesting that PKA
signal could regulate histone methylation and gene tran-
scription [40]. This could be a potential mechanism that
cAMP acts through to favor osteogenesis over adipogenesis
in MSCs. Forskolin did increase PCNA transcript levels in
MSCs (data not shown), suggesting changes in the makeup
of MSC population. As such, activation of cAMP signaling
in BMSCs could be both pro-osteogenic and mitogenic,
resulting in more MSCs directed toward osteogenic lineage
and less MSCs directed toward adipogenic lineage.
PTH can control Wnt signaling in osteoblast lineage
cells via regulation of negative modulators such as Dkk1
and Sclerostin [41, 42]. There is also evidence that the
effect of PTH on the canonical Wnt pathway occurs at least
partially through the cAMP/PKA signaling by differen-
tially regulating Wnt receptor complex proteins and Dkk1
[43]. The role of canonical Wnt signaling in mesenchymal
cell’s ability to differentiate into osteoblasts is unclear.
Wnt stimulation had been reported to regulate osteogenesis
in human MSCs both negatively and positively in a con-
text-specific manner [44]. Maturation state of the osteo-
genic cells also appeared to be important. Activation of
canonical Wnt signal in undifferentiated MSCs and juve-
nile mouse calvarial osteoblasts inhibited osteogenesis, but
strongly induced osteogenesis in mature calvarial osteo-
blasts [45, 46]. When we measured canonical Wnt target
gene expression in MSCs exposed to either forskolin or
PTH for 5 days before induction of osteoblast differentia-
tion, only Axin2 gene expression was significantly upreg-
ulated by forskolin treatment. We also treated MSCs with
Wnt3a for five days to make sure the gene expression of the
selected Wnt target genes could be controlled by Wnt3a.
As expected, Wnt3a was able to upregulate selected Wnt
target genes. Contrary to enhanced osteogenic response
produced by forskolin, osteogenic response followed by
5-day Wnt3a treatment was greatly reduced. Therefore, the
effect of activation of cAMP signaling in MSCs on sub-
sequent osteogenesis was not mediated through the
canonical Wnt pathway.
Previously, several groups had investigated the role of
cAMP in MSC linage specification. A high-throughput
siRNA library screen conducted by Zhao and Ding [31]
identified GNAS (Gas) and ADCY8 (adenylate cyclase 8) as
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genes that suppressed osteogenic specification. The authors
carried out a very similar experiment in which cells were
subjected to specific siRNA knockdowns (initial 2–4 days)
followed by osteogenic induction (additional 5–9 days)
[31]. Gene expression knockdown of these targets genes
enhanced osteogenic maturation. Substituting siRNA with
forskolin suppressed osteogenesis although a human MSC
cell line (PT-2501) was used in their experiments [31]. In
contrast, de Boer and coworkers [28, 29] pretreated human
MSCs derived from bone marrow with db-cAMP or for-
skolin in basic medium and was able to enhance in vivo
bone formation after transplantation. Subsequently, they
proceeded to test the same idea in the rodent models. Db-
cAMP was applied to mouse MSCs in the presence of
mineralization medium for 3 or 10 days. These treatments
suppressed mineralization [33]. As noted, db-cAMP was
present in the mineralization medium in one case but not
the other. It is important to consider the specific type of cell
population in which the cAMP signal is activated, whether
it is homogeneous MSCs, MSCs populated with other
elements of the bone marrow, or MSCs that have been
induced to undergo osteogenesis. In addition, dexametha-
sone was used in these experiments as one of the osteo-
genic inducers, while it was not used in our study. It is a
synthetic member of the glucocorticoid class of steroid
hormones and can exert its influence on lineage commit-
ment through a cAMP/PKA-independent mechanism [47].
PTH and forskolin treatments on BMSCs sometimes
produced different effects on subsequent MSC develop-
ment. Stimulating cAMP signal in BMSCs by forskolin
reduced the efficiency of adipogenesis, whereas PTH
enhanced adipogenesis to a small degree. Forskolin acti-
vation of cAMP signaling in BMSCs favored osteogenesis
over adipogenesis. Exposure to PTH promoted both. This is
in contrast to the findings by Rickard et al. [26] where
intermittent PTH treatment or a non-peptide agonist of
PTH1 receptor suppressed adipocyte differentiation from
human MSCs. However, human MSCs used in these
experiments were relatively homogeneous. In contrast,
BMSCs derived from mouse long bones are heterogeneous,
and it is possible that cells other than MSCs contribute to
the ability of PTH to promote adipogenesis. Furthermore,
Rickard’s human MSCs were cultured and treated with
PTH under mildly adipogenic conditions whereas we
activated PTH and cAMP signaling before adipogenic
induction. Finally, in our case, PTH and forskolin treat-
ments were continuous for five days. In Richard’s experi-
ments, intermittent PTH and forskolin treatments were one
hour per day. Further studies are needed to define the
precise basis for the differences between the present results
and those of Rickard’s et al. [26].
PTH stimulates a diverse range of signaling pathways.
It would be interesting to pharmacologically inhibit
either cAMP/PKA or protein kinase C/MAPK pathway to
discover the contribution of each signaling pathway to
the effects of PTH on osteogenesis and adipogenesis.
However, the different results produced by PTH and
forskolin can also be attributed to the cell types which
express PTH1R to receive the signal. Forskolin treatment
of BMSCs activated cAMP pathway in all cell types in
that population. PTH treatment activated cAMP pathway
only in cells that express PTH1R. Therefore, without
knowing the cell populations that express PTH receptors,
it is difficult to interpret results of pharmacological
manipulation of the downstream pathways of PTH sig-
naling. BMSCs consist of a wide range of cell types,
including cells of hematopoietic lineage. Studies using
genetically modified mice provided evidence that PTH-
mediated anabolic response required participation of cells
of hematopoietic origin [48–50]. Osteopetrotic c-fos-
deficient mice that have osteoclast defect were not
responsive to PTH treatments [49]. Perhaps it is more
important to first identify the cell type(s) in which acti-
vated cAMP signaling can potentiate osteogenesis and to
identify the GPCR(s) that activates cAMP signaling and
can induce a more robust osteogenesis. Recent reports
suggested that Gs- and Gq-coupled A2A and A2B
adenosine receptors played a role in promoting prolifer-
ation and differentiation of bone marrow-derived mes-
enchymal stem cell [51, 52]. In fact, A2B adenosine
receptor knockout mice exhibited lower bone density in
the femur [52]. Moreover, transfection of A2B receptors
into murine osteoblast precursor cell line, 7F2, stimulated
osteocalcin and ALP expression and inhibited subsequent
adipogenesis [53].
In conclusion, activation of cAMP pathway in BMSCs
conditioned MSCs to produce a more efficient osteogenic
response, but a less efficient adipogenic response. On the
other hand, sustained activation of cAMP pathway in
differentiating osteoblasts inhibited mineralization.
Cyclic AMP signaling in BMSCs may have a role in
controlling the balance between adipogenesis and osteo-
genesis, partially by regulating lineage commitment of
MSCs.
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